Amwill Health Care board meet Oct 23: H1 FY27, dividend

What the company has announced to exchanges

Amwill Health Care Ltd has informed BSE that its Board of Directors will meet on October 23, 2026. The agenda includes considering and approving the company’s unaudited financial results for the half year ended September 30, 2026, which is H1 of FY2026-27. The board will also consider whether to declare an interim dividend for equity shareholders. The disclosure was published on October 16, 2026, as a board meeting intimation. This kind of announcement typically draws attention because it sets a defined date for results and potential shareholder distribution.

Board meeting date and agenda: results plus interim dividend

The company has positioned the meeting around two deliverables: taking on record the H1 FY27 unaudited numbers and discussing an interim dividend. In the market summary shown alongside the exchange intimation, the agenda is repeatedly described as “Half Yearly Results & Interim Dividend.” Separately, some listings also show an “Upcoming Result Date” of October 22, 2026. However, the BSE-linked board meeting intimation explicitly mentions the meeting being scheduled for October 23, 2026. For investors tracking corporate actions and results, the exchange intimation date and the scheduled board meeting date remain the most relevant reference points.

Trading window closure under insider trading rules

Amwill Health Care has also confirmed a trading window closure for designated persons. As per the information provided, the trading window has been closed from October 1, 2026. It is expected to reopen 48 hours after the financial results are announced. The company states this is aligned with SEBI’s Prohibition of Insider Trading Regulations and its own insider trading policy. Such closures are standard practice around price-sensitive events like financial results and dividend decisions.

Latest dividend information available so far

The disclosure set includes two dividend references that investors may track. One line states “Latest dividend: 0.5 per share” with an ex-dividend date of August 7, 2026. Another line states the company has declared a 5% dividend with the same ex-date: 07 Aug 26. The October 23 board meeting will consider an interim dividend, but the actual amount, record date, and timeline will only be known if the board approves it and the company makes a further disclosure.

Key dates investors are tracking

The story has two important moving parts: the H1 FY27 results and the dividend decision, both linked to the same board meeting.

Financial snapshot: annual totals and profitability indicators

The dataset also includes a compact annual financial summary (all figures in ₹ crore, unless mentioned otherwise). For FY2026, the company’s Total Revenue is listed at ₹48.41 crore. Profit after tax (PAT) for FY2026 is listed at ₹11.42 crore, with a net profit margin of 25.10% and an operating profit margin of 33.77%. Basic EPS for FY2026 is shown as 5.71.

Standalone half-year sales points shown in the dataset

A separate “Standalone Half Yearly Results” table shows a sales line for a few half-year points. Sales are shown as ₹23 crore for Sep 2024, ₹17 crore for Mar 2025, and ₹21 crore for Sep 2025 (figures shown in ₹ crore). While this table is not complete in the provided extract for every period listed, it provides context that the company has reported mid-year sales figures in that range over the referenced half-year snapshots. Investors typically compare H1 numbers year-on-year once the Sep 2026 half-year results are published.

Dividend payout history shown: payout percentage line

The dataset also includes a “Dividend Payout %” series across multiple fiscal years. For Mar 2021 through Mar 2026, the dividend payout percentage is shown as 0.00 each year. That history is relevant because the board’s consideration of an interim dividend becomes a notable event against a backdrop where the payout percentage line has been displayed as zero across those years. At the same time, the listing also displays a recent dividend event with an ex-date in August 2026, so investors will likely look for clarity on the company’s dividend policy and how interim distributions are being structured.

Market impact: what typically changes after this meeting

The October 23 meeting can influence the near-term information flow for shareholders in two ways: first through the unaudited H1 FY27 numbers, and second through any interim dividend declaration. If an interim dividend is approved, the company would generally follow up with details such as the record date and payment timelines through exchange filings. From a compliance standpoint, the trading window reopening is tied to the timing of the results announcement, which is why the “48 hours after results” clause matters for designated persons. For investors, the key is the official disclosures after the meeting, because those will confirm the results figures, any dividend amount, and the operational timeline for the corporate action.

Why the announcement matters

Board meeting intimations are not performance indicators by themselves, but they provide a date anchor for results and potential capital returns. In Amwill Health Care’s case, the agenda combines financial reporting for the half year ended September 30, 2026 with a dividend discussion, making the meeting more consequential for shareholders who track both earnings and distributions. The annual financial summary included in the dataset provides baseline context, with FY2026 Total Revenue of ₹48.41 crore and PAT of ₹11.42 crore. The next update investors will watch is the company’s exchange filing after the board meeting, which should confirm the unaudited H1 FY27 numbers and whether an interim dividend has been approved.

Conclusion

Amwill Health Care’s board meeting on October 23, 2026 is scheduled to take on record unaudited H1 FY27 results for the half year ended September 30, 2026 and to consider an interim dividend. The trading window has been closed from October 1, 2026 and is expected to reopen 48 hours after the results are announced. The next concrete milestone is the post-meeting exchange disclosure, which should provide the final outcome on both the results approval and the interim dividend decision.